Methods for the treatment of IL-1β related diseases
View Patent ↗Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.
1. A method of treating in a human, Type 2 diabetes, or a Type 2 diabetes-induced disease or condition selected from the group consisting of: insulin resistance, decreased insulin production, hyperglycemia, hyperinsulinemia, and obesity, the method comprising administering an anti-IL-1β antibody or fragment thereof to the human, wherein the antibody or antibody fragment binds to human IL-1β with a dissociation constant of about 250 pM or less.
2. The method of claim 1 , wherein the Type 2 diabetes-induced disease or condition is decreased insulin production.
3. The method of claim 1 , wherein the Type 2 diabetes-induced disease or condition is hyperglycemia.
4. The method of claim 1 , wherein the Type 2 diabetes-induced disease or condition is hyperinsulinemia.
5. The method of claim 1 , wherein the Type 2 diabetes-induced disease or condition is obesity.
6. The method of claim 1 , wherein the Type 2 diabetes-induced disease or condition is insulin resistance.
7. The method of claim 1 , wherein administration of an initial dose of the antibody or antibody fragment is followed by the administration of one or more subsequent doses.
8. The method of claim 7 , wherein administration of an initial dose of the antibody or antibody fragment is followed by the administration of two or more subsequent doses.
9. The method of claim 1 , wherein administration of an initial dose of the antibody or antibody fragment is followed by the administration of one or more subsequent doses, and wherein said one or more subsequent doses are in an amount that is approximately the same or less than the initial dose.
10. The method of claim 1 , wherein administration of an initial dose of the antibody or antibody fragment is followed by the administration of one or more subsequent doses, and wherein at least one of the subsequent doses is in an amount that is more than the initial dose.
11. The method of claim 1 , wherein the antibody or antibody fragment binds to human IL-1β with a dissociation constant of about 10 pM or less.
12. The method of claim 11 , wherein the antibody or antibody fragment binds to human IL-1β with a dissociation constant of about 1 pM or less.
13. The method of claim 12 , wherein the antibody or antibody fragment binds to human IL-1β with a dissociation constant of about 0.5 pM or less.
14. The method of claim 7 , wherein the initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 2 weeks.
15. The method of claim 14 , wherein the initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 1 month.
16. The method of claim 15 , wherein the initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 3 months.
17. The method of claim 16 , wherein the initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 6 months.
18. The method of claim 17 , wherein the initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 12 months.
19. The method of claim 1 , wherein the antibody or antibody fragment is administered in one or more doses of 3 mg/kg or less of antibody or fragment.
20. The method of claim 19 , wherein the antibody or antibody fragment is administered in one or more doses of 1 mg/kg or less of antibody or fragment.
21. The method of claim 20 , wherein the antibody or antibody fragment is administered in one or more doses of 0.5 mg/kg or less of antibody or fragment.
22. The method of claim 21 , wherein the antibody or antibody fragment is administered in one or more doses of 0.1 mg/kg or less of antibody or fragment.
23. The method of claim 22 , wherein the antibody or antibody fragment is administered in one or more doses of 0.03 mg/kg or less of antibody or fragment.
24. The method of claim 23 , wherein the antibody or antibody fragment is administered in one or more doses of 0.01 mg/kg or less of antibody or fragment.
25. The method of claim 19 , wherein the one or more doses are at least 0.01 mg/kg of antibody or fragment.
26. The method of claim 1 , wherein the anti-IL-1β antibody or antibody fragment is a neutralizing antibody.
27. The method of claim 1 , wherein the anti-IL-1β antibody or antibody fragment binds to an IL-1β epitope such that the bound antibody or fragment substantially permits the binding of IL-1β to IL-1 receptor I (IL-1RI).
28. The method of claim 1 , wherein the antibody or antibody fragment does not detectably bind to IL-1α, IL-1R or IL-1Ra.
29. The method of claim 1 , wherein the antibody or antibody fragment binds to an epitope contained in the sequence ESVDPKNYPKKKMEKRFVFNKIE (SEQ ID NO: 1).
30. The method of claim 1 , wherein the antibody or antibody fragment binds to an epitope incorporating Glu64 of IL-1β.
31. The method of claim 1 , wherein the antibody or antibody fragment binds to amino acids 1-34 of the N terminus of IL-1β.
32. The method of claim 1 , wherein the antibody or antibody fragment is human engineered or humanized.
33. The method of claim 1 , wherein the antibody or antibody fragment is human.
34. The method of claim 1 , wherein the anti-IL-1β antibody or antibody fragment is administered by subcutaneous, intravenous or intramuscular injection.
35. The method of claim 1 , wherein the antibody or antibody fragment is administered as a fixed dose, independent of a dose per subject weight ratio.
36. The method of claim 35 , wherein the antibody or antibody fragment is administered in one or more doses of 500 mg or less of antibody or fragment.
37. The method of claim 36 , wherein the antibody or antibody fragment is administered in one or more doses of 250 mg or less of antibody or fragment.
38. The method of claim 37 , wherein the antibody or antibody fragment is administered in one or more doses of 100 mg or less of antibody or fragment.
39. The method of claim 38 , wherein the antibody or antibody fragment is administered in one or more doses of 25 mg or less of antibody or fragment.
40. The method of claim 35 , wherein the antibody or antibody fragment is administered in one or more doses of at least 1 mg of antibody or fragment.
41. The method of claim 35 , wherein the antibody or antibody fragment is administered in one or more doses of about 10 mg to about 100 mg of antibody or fragment.
42. The method of claim 1 , wherein said method is in conjunction with at least one additional treatment method, said additional treatment method comprising administering at least one pharmaceutical composition comprising an active agent other than an IL-1β antibody or antibody fragment.
43. The method of claim 1 , wherein said method prevents or delays the need for at least one additional treatment method, said additional treatment method comprising administering at least one pharmaceutical composition comprising an active agent other than an IL-1β antibody or antibody fragment.
44. The method of claim 1 , wherein said method reduces the amount, frequency or duration of at least one additional treatment method, said additional treatment method comprising administering at least one pharmaceutical composition comprising an active agent other than an IL-1β antibody or antibody fragment.
45. The method of claim 42 , wherein said at least one pharmaceutical composition comprising an active agent other than an IL-1β antibody or antibody fragment is selected from the group consisting of a sulfonylurea, a meglitinide, a biguanide, an alpha-glucosidase inhibitor, a thiazolidinedione, a glucagon-like peptide, and insulin.
46. The method of claim 45 , wherein said active agent is a sulfonylurea.
47. The method of claim 45 , wherein said active agent is a meglitinide.
48. The method of claim 45 , wherein said active agent is a biguanide.
49. The method of claim 45 , wherein said active agent is an alpha-glucosidase inhibitor.
50. The method of claim 45 , wherein said active agent is a thiazolidinedione.
51. The method of claim 45 , wherein said active agent is a glucagon-like peptide.
52. The method of claim 45 , wherein said active agent is insulin.
53. The method of claim 1 , wherein administration of an initial dose of the antibody or antibody fragment is followed by the administration of one or more subsequent doses, and wherein the plasma concentration of said antibody or antibody fragment in the human is maintained at a level of at least about 0.03 μg/ml during a course of treatment with said initial dose and one or more subsequent doses.
54. The method of claim 53 , wherein the plasma concentration of said antibody or antibody fragment is maintained at a level of at least about 0.1 μg/ml during the course of treatment.
55. The method of claim 54 , wherein the plasma concentration of said antibody or antibody fragment is maintained at a level of at least about 0.3 μg/ml during the course of treatment.
56. The method of claim 1 , wherein the antibody or antibody fragment thereof has a lower IC 50 than an IL-1β receptor antagonist in a human whole blood IL-1β inhibition assay that measures IL-1β induced production of IL-8.